Drugs / Gemcitabine
Drug research

Gemcitabine

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Gemzar; gemcitabine hydrocholoride

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic CancerNCT00625586MacroGenicsPhase 2Terminated2009-01-21Actual
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaNCT06390059NVCRPhase 2Completed2025-11-18Actual
A Study of Botensilimab in Participants With Metastatic Pancreatic CancerNCT05630183AGENPhase 2Completed2026-01-05Actual
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPCNCT03257033RenovoRxPhase 3Recruiting2027-06Estimated
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559ALX Oncology Inc.Phase 2Recruiting2027-12Estimated
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)NCT06625320RVMDPhase 3Active not recruiting2026-06Estimated
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerNCT06710288IBRXPhase 2Recruiting2027-05Estimated
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaNCT07259317Corcept TherapeuticsPhase 2Recruiting2027-09Estimated
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerNCT04390399IBRXPhase 2Active not recruiting2025-10-13Actual
A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaNCT05548296Acrivon TherapeuticsPhase 2Recruiting2027-05-30Estimated
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsNCT05712356LSTAPhase 2Completed2026-04-05Actual
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNCT06608927RCUSPhase 3Active not recruiting2030-11-30Estimated
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerNCT03929666Jazz PharmaceuticalsPhase 2Completed2025-08-30Actual
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1NCT05870748STROPhase 2, Phase 3Terminated2025-08-26Actual
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerNCT06282575Jazz PharmaceuticalsPhase 3Recruiting2028-12-01Estimated
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)NCT03377491NVCRPhase 3Completed2024-10-16Actual
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerNCT06435429Jazz PharmaceuticalsPhase 3Recruiting2028-04-28Estimated

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.